RXi to Raise $7.8M in Stock, Warrant Sale | GenomeWeb

RXi Pharmaceuticals this week said it has entered into definitive agreements with undisclosed investors to sell 2,385,715 shares of its common stock at $3.50 per share and warrants to purchase up to 954,286 shares of common stock at an exercise price of $4.50 per share.

The warrants are exercisable beginning on or about Feb. 4, 2010, the company noted.

RXi said it will receive approximately $7.8 million in net proceeds from the offering, which will be used to meet working capital needs and for general corporate purposes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.